Top

Breast Cancer Research and Treatment

Published in:

01-07-2007 | Preclinical Study

MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research

Authors: James M. Rae, Chad J. Creighton, Jeanne M. Meck, Bassem R. Haddad, Michael D. Johnson

Published in: Breast Cancer Research and Treatment | Issue 1/2007

Abstract

Background

The tissue of origin of the cell line MDA-MB-435 has been a matter of debate since analysis of DNA microarray data led Ross et al. (2000, Nat Genet 24(3):227–235) to suggest they might be of melanocyte origin due to their similarity to melanoma cell lines. We have previously shown that MDA-MB-435 cells maintained in multiple laboratories are of common origin to those used by Ross et al. and concluded that MDA-MB-435 cells are not a representative model for breast cancer. We could not determine, however, whether the melanoma-like properties of the MDA-MB-435 cell line are the result of misclassification or due to transdifferention to a melanoma-like phenotype.

Methods

We used karyotype, comparative genomic hybridization (CGH), and microsatalite polymorphism analyses, combined with bioinformatics analysis of gene expression and single nucleotide polymorphism (SNP) data, to test the hypothesis that the MDA-MB-435 cell line is derived from the melanoma cell line M14.

Results

We show that the MDA-MB-435 and M14 cell lines are essentially identical with respect to cytogenetic characteristics as well as gene expression patterns and that the minor differences found can be explained by phenotypic and genotypic clonal drift.

Conclusions

All currently available stocks of MDA-MB-435 cells are derived from the M14 melanoma cell line and can no longer be considered a model of breast cancer. These cells are still a valuable system for the study of cancer metastasis and the extensive literature using these cells since 1982 represent a valuable new resource for the melanoma research community.

Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P et al (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227–235PubMedCrossRef

Thompson EW, Waltham M, Ramus SJ, Hutchins AM, Armes JE, Campbell IG et al (2004) LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. Clin Exp Metastasis 21(6):535–541PubMedCrossRef

Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB et al (2004) Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 64(10):3479–3485PubMedCrossRef

Lee H, Lin EC, Liu L, Smith JW (2003) Gene expression profiling of tumor xenografts: in vivo analysis of organ-specific metastasis. Int J Cancer 107(4):528–534PubMedCrossRef

Jessani N, Liu Y, Humphrey M, Cravatt BF (2002). Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci 99(16):10335–10340PubMedCrossRef

Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55(5):294–299PubMedCrossRef

Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R et al (2004) Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 21(6):543–552PubMedCrossRef

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S et al (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047):117–122PubMedCrossRef

Creighton C, Kuick R, Misek DE, Rickman DS, Brichory FM, Rouillard JM et al (2003) Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol 4(7):R46PubMedCrossRef

10.

Saldanha AJ (2004) Java treeview––extensible visualization of microarray data. Bioinformatics 20(17):3246–3248PubMedCrossRef

11.

Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci 95(25):14863–14868PubMedCrossRef

12.

Barch MJ, Knutsen T, Spurbeck J (eds) (1997) The AGT cytogenetics laboratory manual, 3rd edn. Lippincott, Philadelphia

13.

Shaffer LG, Tommerup N (eds) (1995) International system for human cytogenetic nomenclature. Karger, Basel

14.

Figueiredo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovsky MA, Giatzakis C et al (1999) Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 84(3):1116–1121PubMedCrossRef

15.

Satya-Prakash KL, Pathak S, Hsu TC, Olive M, Cailleau R (1981) Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes. Cancer Genet Cytogenet 3(1):61–73PubMedCrossRef

16.

Cailleau R, Olive M, Cruciger QV (1978) Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14(11):911–915PubMedCrossRef

17.

Price JE, Polyzos A, Zhang RD, Daniels LM (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50(3):717–721PubMed

18.

Chee DO, Boddie AW, Roth JA, Holmes EC, Morton DL (1976) Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. Cancer Res 36(4):1503–1509PubMed

19.

Katano M, Saxton RE, Cochran AJ, Irie RF (1984) Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice. J Cancer Res Clin Oncol 108(2):197–203PubMedCrossRef

Title: MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research
Authors: James M. Rae
Chad J. Creighton
Jeanne M. Meck
Bassem R. Haddad
Michael D. Johnson
Publication date: 01-07-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Breast Cancer Research and Treatment / Issue 1/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-006-9392-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2007

Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF

Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics

The 3′ untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation

Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu

Health-related quality of life in long-term breast cancer survivors: Nationwide survey in Denmark

Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer